CYP3A4 and heart failure: In an analysis restricted to patients taking 5 mg BID, we found renal function, age, sex, body weight, diabetes, heart failure, and use of inhibitors of CYP3A4 or P-gp to be independent clinical predictors of trough apixaban levels.